DPP-4 inhibitor — same mechanism as sitagliptin, linagliptin, saxagliptin (raises endogenous GLP-1 + GIP). Renal dose adjustment needed. Heart failure signal in EXAMINE trial led to FDA boxed warning.
Half-Life & Elimination Curve (PO: 21h)
Plasma (PO)t½ Decay (21h)Effect Site (ke0)
0×t½0h100%(32.9 µg/L)
1×t½21h50%(16.5 µg/L)
2×t½42h25%(8.23 µg/L)
3×t½63h12.5%(4.11 µg/L)
4×t½3.5d6.3%(2.06 µg/L)
5×t½4.4d3.1%(1.03 µg/L)
Elimination t½21h (PO)
Rate Constant (ke)0.033 h⁻¹
Time to Peak (Tmax)5.12h
Est. Peak (Cmax)32.9 µg/L
Clearance (CL)13.8 L/h
97% Washout (5×t½)4.4d
Dosing Guidelines
Oral (PO): Typical 25 mg (Range: 6.25–25 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 65% · Volume of Distribution (Vd): 417 L · Absorption (ka): 0.6 h⁻¹ (t½ka ≈ 1.16h) [PMID 33952821]